Impact of anti-CD20 monoclonal antibodies on serologic response to

Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis

Neutralizing antibody against anti–SARS-CoV-2 vaccination

A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia

Progress with the use of monoclonal antibodies for the treatment of systemic lupus erythematosus

Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma

Production of anti-spike antibodies in response to COVID vaccine in lymphoma patients

Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis

JPM, Free Full-Text

Frontiers Analysis of vaccine responses after anti-CD20 maintenance in B-cell lymphoma in the Balearic Islands. A single reference center experience

Vaccines, Free Full-Text